دورية أكاديمية
GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
| العنوان: | GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach |
|---|---|
| المؤلفون: | CRISCI, ISABELLA, Aragona, Michele, Politi, Konstantina Savvina, DANIELE, GIUSEPPE, DEL PRATO, STEFANO |
| المساهمون: | Crisci, Isabella, Aragona, Michele, Politi, Konstantina Savvina, Daniele, Giuseppe, DEL PRATO, Stefano |
| سنة النشر: | 2015 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | Continuous glucose monitoring, Glycemic variability, Insulin pump therapy, Liraglutide, Type 1 diabete, Adult, Aged, Area Under Curve, Blood Glucose, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 1, Female, Glucagon-Like Peptide-1 Receptor, Hemoglobin A, Glycosylated, Human, Hypoglycemia, Hypoglycemic Agent, Male, Middle Aged, Endocrinology, Internal Medicine, Diabetes and Metabolism |
| الوصف: | Aims: To test potential efficacy of liraglutide, a GLP-1 receptor agonist, in subjects with type 1 diabetes (T1DM). Methods: We have recruited nine T1DM patients (age 40.1±6.4years, duration of diabetes 19.2±8.8years, BMI 24.3±3.5kg/m2, HbA1c 8.2±1.0%–66±11mmol/mol, daily insulin dose: 0.6±0.1IU/kg) on continuous subcutaneous insulin therapy with undetectable C-peptide. In addition to existing treatment was administered in single-blind (a) therapy subcutaneously with 0.1ml of saline solution for 3days and (b) 0.1ml of liraglutide (0.6mg/day) for a further 3days with daily glucose excursions recorded by continuous glucose monitoring. Results: Adding liraglutide resulted in a significant reduction in mean blood glucose (138±29 vs. 163±29mg/dl, p<0.0001) and standard deviation (42±9 vs. 60±15mg/dl, p<0.0001). The area under the curve (AUC) for blood glucose >140mg/dl was also significantly reduced (22.2±16.4 vs. 41.1±19.7mg/dlh, p<0.05) with no difference in AUC for blood glucose <70mg/dl (liraglutide 0.7±0.9mg/dlh; placebo: 0.8±1.4mg/dlh, p=NS). Finally, adding liraglutide reduced daily insulin requirement (37.5±17.2 vs. 42.9±22.4 UI/day, p<0.01). Conclusions: Short-term treatment with liraglutide, in T1DM, reduces average blood glucose, blood glucose variability and daily insulin requirement without increasing risk of hypoglycemia. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26293127; info:eu-repo/semantics/altIdentifier/wos/WOS:000363950500014; volume:52; issue:6; firstpage:1129; lastpage:1133; numberofpages:5; journal:ACTA DIABETOLOGICA; http://hdl.handle.net/11568/763653Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84945461146; link.springer.de/link/service/journals/00592/index.htm |
| DOI: | 10.1007/s00592-015-0800-6 |
| الإتاحة: | https://doi.org/10.1007/s00592-015-0800-6Test http://hdl.handle.net/11568/763653Test |
| رقم الانضمام: | edsbas.470545AE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00592-015-0800-6 |
|---|